GlassScriptPhysician profile
William W Hardy
NPI 1144400839
$3,860.81
in general payments reported to CMS, 2019-2025
35 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $280 · 2021: $394 · 2022: $704 · 2023: $697 · 2024: $730 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $652.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $376.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $320.84 | 2019-2025 | |
| Astellas Pharma US INC | $302.65 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.07 | 2020-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $191.03 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $185.60 | 2022-2023 | |
| Abbvie INC. | $162.82 | 2020-2024 | |
| Lilly USA, LLC | $124.26 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $107.92 | 2019-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $105.68 | 2019-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.47 | 2019-2025 | Jardiance |
| Abbott Laboratories | $93.70 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Edwards Lifesciences Corporation | $80.90 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $79.76 | 2019-2023 | Breztri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $75.59 | 2021-2023 | Aplenzin |
| Janssen Pharmaceuticals, INC | $69.66 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $62.49 | 2023-2024 | Gemtesa |
| Allergan, INC. | $60.45 | 2019-2020 | |
| Shockwave Medical, INC | $55.46 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $55.01 | 2024-2025 | Angio-Seal, Azur Cx Detachable |
| Mckesson Medical-Surgical, INC. | $46.66 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $44.86 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $41.22 | 2021 | |
| Esperion Therapeutics, INC. | $30.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.76 | 2021 | |
| Angiodynamics, INC. | $29.23 | 2025 | Auryon Laser System 100-120 Vac |
| Seqirus USA INC | $28.28 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $25.53 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $20.93 | 2023 | Quviviq |
| Medtronic USA, INC. | $20.71 | 2019 | |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $15.15 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.32 | 2019 | |
| Dexcom, INC. | $13.28 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.